Table 5.
Numbers needed to treat with posaconazole to prevent IFI and death [41]
| Antifungal prophylaxis during neutropenia | Antifungal prophylaxis during GVHD | |||||
|---|---|---|---|---|---|---|
| Clinical outcome | Posaconazole 200 mg tid | Fluconazole 400 mg od; itraconazole 200 mg bid | NNT | Posaconazole 200 mg tid | Fluconazole 400 mg od | NNT |
| IFI | 2.3% | 8.4% | 16 | 5.3% | 9% | 27* |
| Invasive aspergillosis | 0.7% | 6.7% | 17 | 2.3% | 7% | 21 |
| Death due to IFI | 1.6% | 5.4% | 27 | 0.7% | 3.7% | 33 |
| Death due to any cause | 14.5% | 21.5% | 14 | 25.2% | 28.1% | 35* |
*
Not significant. Bid, twice daily; IFI, invasive fungal infection; GVHD, graft-versus-host disease; NNT, number needed to treat; od, once daily; tid, three times daily.